Ambrilia, TaiMed deal

TaiMed received exclusive, worldwide rights from Ambrilia to develop, manufacture and commercialize protease inhibitor (PI) and integrase inhibitor programs for HIV/AIDS infection. Ambrilia received $250,000 up front and is eligible for up to $7.6 million in milestones. The PI program includes PPL-100, a phosphorylated prodrug of PL-100, a PI which has completed Phase I testing. Ambrilia's integrase inhibitor program is in discovery. ...